

Adam L Cohen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6482654/publications.pdf>

Version: 2024-02-01

37
papers

3,057
citations

394421

19
h-index

345221

36
g-index

40
all docs

40
docs citations

40
times ranked

6069
citing authors

#	ARTICLE	IF	CITATIONS
1	Caregiver burden by treatment and clinical characteristics of patients with glioblastoma. <i>Supportive Care in Cancer</i> , 2022, 30, 1365-1375.	2.2	8
2	Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer. <i>Nature Communications</i> , 2021, 12, 3039.	12.8	24
3	Serial single-cell genomics reveals convergent subclonal evolution of resistance as patients with early-stage breast cancer progress on endocrine plus CDK4/6 therapy. <i>Nature Cancer</i> , 2021, 2, 658-671.	13.2	34
4	Novel temporal and spatial patterns of metastatic colonization from breast cancer rapid-autopsy tumor biopsies. <i>Genome Medicine</i> , 2021, 13, 170.	8.2	5
5	Association between the 21-gene recurrence score and isolated locoregional recurrence in stage I-II, hormone receptor-positive breast cancer. <i>Radiation Oncology</i> , 2020, 15, 198.	2.7	4
6	Repeat radiation with bevacizumab and minocycline in bevacizumab-refractory high grade gliomas: a prospective phase 1 trial. <i>Journal of Neuro-Oncology</i> , 2020, 148, 577-585.	2.9	7
7	The contribution of the rs55705857 G allele to familial cancer risk as estimated in the Utah population database. <i>BMC Cancer</i> , 2019, 19, 190.	2.6	2
8	Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. <i>Nature Medicine</i> , 2019, 25, 477-486.	30.7	932
9	Opportunities for improving cancer treatment using systems biology. <i>Current Opinion in Systems Biology</i> , 2019, 17, 41-50.	2.6	5
10	Challenges of targeting <i>BRAF</i> V600E mutations in adult primary brain tumor patients: a report of two cases. <i>CNS Oncology</i> , 2019, 8, CNS48.	3.0	17
11	Patterns of care and outcomes in gliosarcoma: an analysis of the National Cancer Database. <i>Journal of Neurosurgery</i> , 2018, 128, 1133-1138.	1.6	37
12	ACTR-19. A MULTICENTER PILOT PHASE II STUDY OF CONTINUING TMZ WITH THE ADDITION OF DISULFIRAM AND COPPER FOR REFRACTORY GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi15-vi15.	1.2	0
13	HOUT-01. A RETROSPECTIVE ANALYSIS OF OUTCOMES WITH TEMOZOLOMIDE AS INITIAL TREATMENT OF GRADE 2 OLIGODENDROGLIOMA. <i>Neuro-Oncology</i> , 2018, 20, vi113-vi113.	1.2	0
14	PATH-54. UTILITY OF NEXT GENERATION SEQUENCING IN ADULT PRIMARY BRAIN TUMORS: IMPACT ON DIAGNOSIS AND PERSONALIZED THERAPY. <i>Neuro-Oncology</i> , 2018, 20, vi170-vi170.	1.2	0
15	Leptomeningeal dissemination of a low-grade lumbar paraganglioma: case report. <i>Journal of Neurosurgery: Spine</i> , 2017, 26, 501-506.	1.7	10
16	New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 19.	4.2	87
17	Glioma Subclassifications and Their Clinical Significance. <i>Neurotherapeutics</i> , 2017, 14, 284-297.	4.4	471
18	A Phase I Study of Neoadjuvant Chemotherapy With Nab-Paclitaxel, Doxorubicin, and Cyclophosphamide in Patients With Stage II to III Breast Cancer. <i>Clinical Breast Cancer</i> , 2017, 17, 503-509.	2.4	7

#	ARTICLE	IF	CITATIONS
19	POWERPIINC (PreOperative Window of Endocrine TheRapy Provides Information to Increase) Tj ETQq1 1 0.784314 rgBT /Overlock 10 tamoxifen. Breast, 2017, 31, 219-223.	2.2	10
20	Combating subclonal evolution of resistant cancer phenotypes. Nature Communications, 2017, 8, 1231.	12.8	124
21	Mechanisms and clinical implications of tumor heterogeneity and convergence on recurrent phenotypes. Journal of Molecular Medicine, 2017, 95, 1167-1178.	3.9	34
22	IGFBP2 expression predicts IDH-mutant glioma patient survival. Oncotarget, 2017, 8, 191-202.	1.8	30
23	A phase I trial of azacitidine and nanoparticle albumin bound paclitaxel in patients with advanced or metastatic solid tumors. Oncotarget, 2017, 8, 52413-52419.	1.8	21
24	Development of the Electronic Social Network Assessment Program Using the Center for eHealth and Wellbeing Research Roadmap. JMIR Human Factors, 2017, 4, e23.	2.0	18
25	Integrative analyses reveal signaling pathways underlying familial breast cancer susceptibility. Molecular Systems Biology, 2016, 12, 860.	7.2	14
26	Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future. Current Treatment Options in Oncology, 2016, 17, 42.	3.0	95
27	Gene-expression patterns in peripheral blood classify familial breast cancer susceptibility. BMC Medical Genomics, 2015, 8, 72.	1.5	13
28	Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas. Neurosurgical Focus, 2015, 38, E2.	2.3	42
29	DNA copy number analysis of Grade II and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status. Acta Neuropathologica Communications, 2015, 3, 34.	5.2	64
30	Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 5425-5430.	7.1	190
31	Glioma Biology and Molecular Markers. Cancer Treatment and Research, 2015, 163, 15-30.	0.5	161
32	Genomic classification of the RAS network identifies a personalized treatment strategy for lung cancer. Molecular Oncology, 2014, 8, 1339-1354.	4.6	14
33	Genomic pathway analysis reveals that EZH2 and HDAC4 represent mutually exclusive epigenetic pathways across human cancers. BMC Medical Genomics, 2013, 6, 35.	1.5	36
34	IDH1 and IDH2 Mutations in Gliomas. Current Neurology and Neuroscience Reports, 2013, 13, 345.	4.2	469
35	A pharmacogenomic method for individualized prediction of drug sensitivity. Molecular Systems Biology, 2011, 7, 513.	7.2	43
36	Risk Reduction Strategies for Ductal Carcinoma In Situ. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 1211-1217.	4.9	2

#	ARTICLE	IF	CITATIONS
37	The relationship between monoclonal gammopathy of undetermined significance and venous thromboembolic disease. <i>Thrombosis Research</i> , 2010, 125, 216-219.	1.7	20